<DOC>
	<DOCNO>NCT02675452</DOCNO>
	<brief_summary>At least one dose level AMG 176 achieve acceptable safety tolerability subject relapse refractory multiple myeloma</brief_summary>
	<brief_title>AMG 176 First Human Trial Subjects With Relapsed Refractory Multiple Myeloma .</brief_title>
	<detailed_description>This Phase 1 , first-in-human , multicenter ; non-randomized , open-label dose-exploration study AMG 176 administer IV subject relapse refractory multiple myeloma . The study conduct three part .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>INCLUSION CRITERIA : Pathologically document , multiple myeloma relapse refractory disease least 2 line therapy , Must willing able undergo bone marrow biopsy screening , Measurable disease per IMWG response criterion , Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 2 , Satisfactory hematological function without transfusion growth factor support , Subjects receive platelet transfusion least 1 week prior screening , Hemoglobin &gt; 8 g/dL , Subjects may receive RBC transfusion receive supportive care ) , Other Inclusion Criteria May Apply . EXCLUSION CRITERIA : Previously receive allogeneic stem cell transplant within 6 month OR receive immunosuppressive therapy within last three month OR sign symptom acute chronic graftversushost disease , Autologous stem cell transplant le 90 day prior study day 1 , Multiple myeloma IgM subtype , POEMS syndrome , Existing plasma cell leukemia , Waldenstrom 's macroglobulinemia , Amyloidosis , Glucocorticoid therapy ( prednisone &gt; 30 mg/day equivalent ) within 7 day prior start treatment , Topical inhale corticosteroid permit , Infection require intravenous antiinfective treatment within 1 week study enrollment ( day 1 ) , Other exclusion Criteria May Apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>